ATS View
한국어

NGeneBio KRX:354200KOSDAQ

엔젠바이오 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked21since Sep 11

In Q2 2026, NGeneBio reported revenue of ₩12.5bn, up 573.8% year on year, and an operating loss of ₩1.2bn. NGeneBio (엔젠바이오) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 30 with 1 article.

Filing signals 4 quarters of losses Screener

NGeneBio quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩12.5bn+573.8%−₩1.2bn
margin −9.5%		−₩3.5bn
Q1 2026₩12.0bn+487.1%−₩1.6bn
margin −13.1%		−₩4.2bn
Q4 2025 derived₩12.0bn+1570.7%−₩1.9bn
margin −15.9%		₩4.3bn
Q3 2025₩5.4bn+162.1%−₩1.6bn
margin −30.3%		−₩1.9bn
Q2 2025₩1.8bn-8.9%−₩2.7bn
margin −145.2%		−₩6.1bn
Q1 2025₩2.0bn+133.1%−₩2.9bn
margin −140.4%		−₩3.0bn
Q4 2024 derived₩717m-40.4%−₩4.5bn−₩3.3bn
Q3 2024₩2.1bn+132.7%−₩4.1bn
margin −198.6%		−₩4.6bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

NGeneBio top stories 2 weeks, by number of outlets

  1. 1
    엔젠바이오 주가 신바…NGS 정밀 진단 기술력 호재에 폭주
    1 outlets · 1 articlesFirst report Oct 30 15:22 핀포인트뉴스

Latest NGeneBio news Korean headlines